Moderna Inc. has announced the full approval from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine, Spikevax, specifically for children aged 6 months through 11 years who are at increased risk for COVID-19 disease. This approval marks a significant step as the vaccine, previously available under Emergency Use Authorization for pediatric populations, can now be administered with full approval in this age group. Moderna's CEO, Stéphane Bancel, emphasized the importance of vaccination for protecting children, especially those with underlying health conditions. The company plans to have the updated Spikevax vaccine available in the U.S. for the 2025-2026 respiratory virus season.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.